DARZALEX FASPRO® demonstrated a clinical response in newly diagnosed and relapsed or refractory multiple myeloma

In the PLEIADES trial, the primary endpoint in both DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) plus bortezomib, melphalan, and prednisone (DVMP) and DARZALEX FASPRO® plus lenalidomide and dexamethasone (DRd) arms was overall response rate (ORR).1


CI=confidence interval; CR=complete response; DRd=DARZALEX FASPRO® (D) + lenalidomide (R) + dexamethasone (d); DVMP=DARZALEX FASPRO® (D) + bortezomib (V) + melphalan (M) + prednisone (P); ORR=overall response rate; PR=partial response; sCR=stringent complete response; VGPR=very good partial response.

*Based on treated subjects.

Examine how DARZALEX® + Rd demonstrated superior efficacy to Rd alone in newly diagnosed, transplant-ineligible multiple myeloma